What if a common Japanese stew ingredient could rebuild your torn knee ligament? That's not a supplement pitch; it's real regenerative medicine. A Japanese university startup has developed technology to strip cow tendon of its cells, leaving behind a collagen scaffold that your own body gradually transforms into a living ligament. Clinical trials are already underway. Here's how beef tendon is becoming the future of sports medicine.

The ACL Tear: Sports' Most Feared Injury

Soccer, basketball, skiing. When the knee twists violently during a sudden change of direction or an awkward landing, the anterior cruciate ligament (ACL) can snap. It's an injury that dominates sports headlines worldwide and can derail careers at every level, from weekend warriors to Olympic athletes.

The numbers are staggering: an estimated 19,000 ACL reconstruction surgeries per year in Japan, 175,000 in the United States, and over 800,000 globally.

The problem lies in how the injury is currently treated. The worldwide standard for ACL reconstruction involves harvesting a tendon from the patient's own body, typically the hamstring tendon from behind the thigh or the patellar tendon below the kneecap. This means damaging a healthy part of the body to fix the injured one.

The drawbacks are significant: muscle weakness at the harvest site, risk of nerve damage, lingering pain, reduced knee extension. And if the reconstructed ligament tears again, which happens roughly 10% of the time, there may not be enough remaining tendon to work with. For athletes, the psychological burden of re-injury anxiety persists long after physical recovery.

Beef Tendon Becomes a Ligament: The Waseda University Breakthrough

Tackling this challenge head-on is a research team led by Professor Kiyotaka Iwasaki of Waseda University's Faculty of Science and Engineering, along with CoreTissue BioEngineering (CTBE), a startup founded in 2016.

Their approach starts with a surprisingly straightforward idea: repurposing cow tendon, known in Japanese food culture as "gyusuji" (牛すじ), a beloved ingredient in oden (Japanese winter hot pot) and simmered dishes, as a medical implant material.

Collagen structures are remarkably similar across mammalian species, and bovine tendon has the thickness and strength needed for ACL reconstruction. But transplanting animal tissue directly into a human body would trigger immune rejection and inflammation.

That's where "decellularization" technology comes in. This process removes only the cellular components that cause immune reactions while preserving the collagen-based structural framework of the tissue.

The Core Innovation: Microwaves Meet Pulsating Flow

What makes Professor Iwasaki's method groundbreaking is its ability to handle thick tissue, something previous decellularization approaches struggled with.

The process works by pumping a specialized cell-dissolving solution through the bovine tendon under rhythmic, pulsating pressure while simultaneously applying microwave irradiation. This combination removes virtually all cellular components without damaging the tissue's structural integrity.

The concept of decellularization has existed for about two decades, but nobody had successfully applied it to thick, dense tissue like tendon while also maintaining the mechanical strength needed for load-bearing applications. Professor Iwasaki's team also developed proprietary freeze-drying and ethylene oxide gas sterilization methods that preserve tissue strength, plus a rehydration technique to restore the tissue to a moisture-containing state after sterilization.

The resulting product isn't "raw cow tendon" being implanted into humans. After decellularization, what remains is essentially a collagen framework, a scaffold. Once implanted in the body, the patient's own cells gradually migrate into this scaffold and begin producing new tissue. Over time, the scaffold transforms into the patient's own living ligament, literally becoming "humanized."

Proven in Sheep: Functioning as "Your Own Ligament" After One Year

This technology has been validated in a large-scale animal study involving 56 sheep.

Researchers performed ACL reconstruction using both decellularized bovine tendon and the sheep's own tendon, then compared results at 3 months and 12 months. The decellularized bovine grafts showed solid attachment between the reconstructed tissue and bone. Critically, collagen density increased between 3 and 12 months, evidence that the host's own cells were infiltrating the scaffold and regenerating tissue.

A separate 52-week study in rats confirmed that decellularized bovine tendon grafts achieved cell infiltration and tissue integration comparable to autografts (the animal's own tendon), with no excessive inflammatory response at any time point.

Clinical Trials Launched: Targeting Commercialization by 2028

In August 2024, CTBE's investigational medical device "CT-ACL001" received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to proceed with clinical trials. The trial began at Tokyo Women's Medical University in November 2024.

An initial safety cohort of 7 patients was followed by a randomized, multi-center trial across 6 facilities nationwide involving approximately 60 patients, comparing the new device against the current standard treatment.

The research is supported by the Japan Agency for Medical Research and Development (AMED). If all goes well, commercialization is projected for around 2028.

In November 2025, CTBE completed a Series A extension round raising 600 million yen (approximately $4 million), with Nippon Ham, one of Japan's largest meat processing companies, and Mitsui Sumitomo Insurance Capital joining as new investors. By January 2026, the company had begun developing mass production equipment.

From Food Waste to Life-Saving Medical Device: Connecting Two Worlds

What makes this story compelling goes beyond medical innovation.

In Japan, "gyusuji" is used in oden, curry, and simmered dishes, but compared to premium cuts like sirloin or tenderloin, consumption is minimal, and much of it is actually discarded. CTBE's technology is essentially upcycling food industry waste into high-value medical devices.

Nippon Ham's investment reflects the potential for advanced utilization of livestock resources. If an inexpensive food byproduct can become a device that saves athletes' careers and improves patients' quality of life, it could create an entirely new revenue stream for the livestock industry. Food and medicine, sports and farming: completely separate worlds connected by a single "suji" (tendon).

Global Context: Xenografts at the Frontier of Regenerative Medicine

Research on using decellularized animal tissue for ligament reconstruction is active worldwide.

UK-based Tissue Regenix has developed "OrthoPure XT," a decellularized porcine (pig) digital extensor tendon xenograft. Their 5-year clinical study of 40 patients reported safety and performance outcomes comparable to autograft and allograft.

However, CTBE's approach has several distinctive strengths: bovine tendon provides sufficient diameter (8mm+) more reliably than porcine alternatives; the microwave-assisted decellularization and strength-preserving sterilization technologies are proprietary inventions; and the platform is being designed for application beyond the knee, including rotator cuff repair in the shoulder and Tommy John surgery (ulnar collateral ligament reconstruction in the elbow), which famously affects baseball pitchers like Shohei Ohtani.

CTBE has also been accepted into Johnson & Johnson Innovation's program in Boston and Mitsubishi Corporation's R Accelerator Program in North America, actively pursuing U.S. market entry and regulatory strategy.

What About Your Country?

A humble hot pot ingredient is being reimagined as a cutting-edge regenerative medicine material. Food waste utilization, reduced patient burden, accelerated athlete recovery, this research has the potential to address multiple societal challenges simultaneously.

What's the conversation around regenerative medicine and xenotransplantation like in your country? Are there examples of food industry and healthcare collaborating in innovative ways? We'd love to hear your perspective.

References